AF9 Antikörper (C-Term)

Produktnummer ABIN5537118

Produktdetails anti-AF9 Antikörper

Target: AF9 (MLLT3) (Protein AF-9 (MLLT3))

Bindungsspezifität: AA 471-502, C-Term

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser AF9 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Aufreinigung: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis

Immunogen: This AF9 (MLLT3) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 471-502 amino acids from the C-terminal region of human AF9 (MLLT3).

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: For WB starting dilution is: 1:1000

For IHC-P starting dilution is: 1:50~100

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 2 mg/mL

Buffer: Supplied in PBS with 0.09 % (W/V) sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Details zu AF9

Target: AF9 (MLLT3) (Protein AF-9 (MLLT3))

Andere Bezeichnung: AF9 (MLLT3 Produkte)

Synonyme: fc39c11 antikoerper, wu:fc39c11 antikoerper, zgc:110210 antikoerper, AF9 antikoerper, YEATS3 antikoerper, 2210011H10Rik antikoerper, 2610012I03Rik antikoerper, 3830408D16Rik antikoerper, Af9 antikoerper, D4Ertd321e antikoerper, Af-9 antikoerper, MLLT3, super elongation complex subunit antikoerper, myeloid/lymphoid or mixed-lineage leukemia; translocated to, 3 antikoerper, mllt3 antikoerper, MLLT3 antikoerper, Mllt3 antikoerper

Hintergrund: The human AF9 gene is one of the most common fusion partner genes with the ALL1 gene at 11q23 (also called MLL), resulting in the t(9,11)(p22,q23). The AF9 gene is more than 100 kb, and 2 patient breakpoint cluster regions (BCRs) have been identified, BCR1 is within intron 4, previously called site A, whereas BCR2 or site B spans introns 7 and 8. Several different structural elements have been identified in AF9, including a colocalizing in vivo DNA topo II cleavage site and an in vitro DNase I hypersensitive (DNase 1 HS) site in intron 7 in BCR2. Reversibility experiments demonstrated a religation of the topo II cleavage sites. In addition, 2 scaffold associated regions (SARs) are located centromeric to the topo II and DNase I HS cleavage sites and border breakpoint regions in 2 leukemic cells lines: SAR1 is located in intron 4, whereas SAR2 encompasses parts of exons 5-7. The patient breakpoint regions of AF9 share the same structural elements as the MLL BCR. A DNA breakage and repair model for nonhomologous recombination between MLL and its partner genes, particularly AF9, has been proposed.

Molekulargewicht: 63 kDa

Gen-ID: 4300

UniProt: P42568